U.S. Chondroplasty Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Chondroplasty
- ✓Market Size 2024: USD 1.9 billion
- ✓Market Size 2032: USD 2.9 billion
- ✓CAGR: 5.3%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock ASC channel now: Device entrants should secure group purchasing and ASC distribution contracts for single-use knee arthroscopy kits by Q4 2026, ahead of the next CMS ASC list cycle. Pair launches with CPT 29877 coding support to protect reimbursement.
Chondroplasty in the United States: Market Overview
The United States generates the largest chondroplasty procedure volume globally, supported by high rates of knee arthroscopy and a large population of active adults with cartilage lesions. Chondroplasty, the debridement or smoothing of damaged articular cartilage, is usually performed during diagnostic or meniscal arthroscopy rather than purchased as a standalone product. The market is therefore defined by surgical volumes and reimbursement codes as much as by device sales. Unlike global markets, where cartilage repair implants dominate spending in Europe and Asia, U.S. revenue concentrates in arthroscopic consumables, energy devices and a narrow set of FDA-approved biologic implants.
The U.S. market is estimated at USD 1.9 billion in 2024, spanning arthroscopic consumables, radiofrequency and mechanical shaver systems, and cartilage repair implants. Knee accounts for most cases, while ankle and hip chondroplasty remain niche. Spending is skewed: a shaving procedure costs a fraction of an autologous chondrocyte implantation case, so implant products generate outsized revenue per patient despite lower volumes. Growth is concentrated where implant-based cases move into outpatient settings.
Growth Drivers in U.S. Chondroplasty
Demographics provide the strongest demand driver. The U.S. Census Bureau projects Americans aged 65 and older to exceed 70 million by 2030, and degenerative cartilage loss rises steeply in this cohort. Active baby boomers also seek joint preservation to delay total knee arthroplasty, which expands the eligible pool for chondroplasty and cartilage repair. Sports participation among adults over 35 adds a second patient group, particularly in running, pickleball and recreational basketball injuries.
Site-of-service policy is the second driver. CMS has progressively added arthroscopic knee procedures to the Medicare Ambulatory Surgical Center Covered Procedures List, moving cases from hospital outpatient departments into lower-cost settings. Third, FDA marketing authorization of cartilage repair products, including MACI from Vericel Corporation and Agili-C from Smith+Nephew, has created reimbursable implant options. Together these factors lift both case volume and implant penetration.
Market Restraints and Entry Barriers in the United States
Regulatory and reimbursement hurdles define the first barrier. Cartilage implants require Premarket Approval under 21 CFR Part 814, a process that typically demands multi-year clinical data before commercial launch. Chondroplasty itself falls under CPT 29877, which National Correct Coding Initiative edits frequently bundle with meniscectomy and other knee arthroscopy codes. New entrants therefore struggle to earn separate payment unless surgeons document distinct defects in operative notes.
Incumbent advantages form the second barrier. Arthrex, Smith+Nephew and Stryker hold installed arthroscopy tower bases in most U.S. hospitals, and value analysis committees hesitate to add competing consumables. Group purchasing contracts through Vizient and Premier lock pricing for multi-year terms. Commercial payers also apply prior authorization to implant procedures, adding administrative delay that slows adoption of new cartilage products.
Market Opportunities in the United States
The clearest near-term opportunity sits in ambulatory surgery centers. Knee arthroscopy volumes in ASCs are growing faster than hospital volumes, and per-case disposable kits suit the economics of freestanding facilities. An addressable pool of roughly USD 400 million in single-use arthroscopic consumables and radiofrequency probes exists within ASC settings, offering entrants a route around hospital contracting. Suppliers offering sterile, single-use kits with same-day delivery can capture share quickly.
Biologic cartilage repair offers the second opportunity. Vericel's MACI platform, with an arthroscopic delivery pathway in development, shifts implantation toward less invasive procedures. Kolon TissueGene's TG-C, a cell and gene therapy for knee osteoarthritis, remains in U.S. Phase 3 development, and its approval would open a disease-modifying category adjacent to chondroplasty. Implant-based chondroplasty spend is estimated at USD 600 million by 2032, concentrated in specialty orthopedic practices.
Chondroplasty at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.9 billion |
| Market Size 2032 | USD 2.9 billion |
| Growth Rate (CAGR) | 5.3% |
| Most Critical Decision Factor | Reimbursement coding and ASC site-of-service eligibility |
| Largest Region | South Region |
| Competitive Structure | Concentrated implants; fragmented arthroscopic consumables |
Leading Market Participants
- Vericel Corporation
- Smith+Nephew
- Arthrex
- Zimmer Biomet
- Stryker
- DePuy Synthes
- Conmed Corporation
- Anika Therapeutics
- Kolon TissueGene
- Ortho Regenerative Technologies
Regulatory and Policy Environment for U.S. Chondroplasty
FDA's Center for Devices and Radiological Health regulates chondroplasty products. Implants follow Premarket Approval under 21 CFR Part 814 with MDUFA V review goals of 180 FDA days for original applications. Arthroscopic instruments usually clear through 510(k) under 21 CFR Part 807. Manufacturers must also meet the Quality Management System Regulation, which aligns with ISO 13485 and takes effect February 2, 2026, requiring documented design controls.
Reimbursement rules run through the Centers for Medicare and Medicaid Services. The annual Medicare Physician Fee Schedule sets surgeon payment under CPT 29877, while the Hospital Outpatient Prospective Payment System and the ASC payment system determine facility reimbursement. CMS proposes ASC Covered Procedures List updates each summer and finalizes them in late autumn, with changes effective January 1. Entrants should track these cycles to time product launches and contract negotiations.
Long-Term Outlook for U.S. Chondroplasty
By 2032 the U.S. chondroplasty market is projected to reach USD 2.9 billion, growing at a 5.3% CAGR. Consumables and energy devices will remain the largest revenue pool by volume, while implant products will expand their share of total value as ASCs add cartilage repair cases. Knee will account for the majority of procedures throughout the forecast period.
Competitive intensity will rise as Smith+Nephew, Arthrex and Vericel defend implant share against smaller entrants with scaffold and allograft technologies. Policy risk remains concentrated in Medicare coding, and any NCCI revision separating chondroplasty from meniscectomy would reshape pricing. Entrants that document separate-defect cases and secure ASC contracts by 2028 will hold defensible positions.
Frequently Asked Questions
Market Segmentation
- Microfracture
- Autologous Chondrocyte Implantation
- Osteochondral Autograft Transfer
- Cartilage Scaffold Implants
- Arthroscopic Debridement
- Ambulatory Surgery Centers
- Hospitals
- Orthopedic Specialty Clinics
- Sports Medicine Centers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.